DJIA 17,810.06 91.06 0.51%
NASDAQ 4,712.97 11.10 0.24%
S&P 500 2,063.50 10.75 0.52%
market minute promo


3.39 0.22 (6.94%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $3.39 6.94%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.23
Previous Close $3.17
Daily Range $3.19 - $3.45
52-Week Range $2.97 - $10.29
Market Cap $351.5M
P/E Ratio -4.46
Dividend (Yield) $0.00 (0.0%)
Volume 4,459,129
Average Daily Volume 1,689,503
Current FY EPS -$0.78





VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

For This Obesity Drug, Europe Trumps the U.S.

Europe is key for Orexigen's Contrave. Shares jumped despite problems with the U.S. launch.

Arena Pharmaceuticals: Belviq Sales Take A Modest Dip With Holiday

Why VIVUS (VVUS) Might Be a Diamond in the Rough - Tale of the Tape

Janssen Is Working Its Way Toward Anti-Obesity

EnteroMedics May Enter The Obesity Space - What Does It Mean?

The 52-Week Low Club for Monday

What's Driving Orexigen Therapeutics Higher?

Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog

Bel-Phen Pilot Study News, Hold On To Your Shares

Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?

Arena Pharmaceuticals stock has fallen hard after a slower than expected launch of its fat-fighting pill Belviq. During its third-quarter conference call, though, management gave three reasons investors should be optimistic moving forward.

See More VVUS News...

VVUS's Top Competitors

VVUS $3.39 (6.94%)
Current stock: VVUS
JNJ $107.86 (0.35%)
Current stock: JNJ
NVS $94.98 (-0.30%)
Current stock: NVS
RHHBY $37.33 (-0.93%)
Current stock: RHHBY